30 results about "Donor derived" patented technology

The present invention provides a method of treating a disease in a subject in need thereof via non-syngeneic graft administration without or with reduced concomitant graft rejection. The method comprises administering to the subject a therapeutically effective graft being non-syngeneic with the subject, and a dose of tolerogenic cells being non-syngeneic with both the subject and the graft for preventing or reducing graft rejection in the subject, thereby treating the disease in the subject.

The present invention provides a method of treating a disease in a subject in need thereof via non-syngeneic graft administration without or with reduced concomitant graft rejection. The method comprises administering to the subject a therapeutically effective graft being non-syngeneic with the subject, and a dose of tolerogenic cells being non-syngeneic with both the subject and the graft for preventing or reducing graft rejection in the subject, thereby treating the disease in the subject

The invention relates to a gene QDTY 2.9IR66897B capable of obviously increasing rice reproductive-stage drought tolerance and a molecular marker method thereof, belonging to the fields of rice high-yield stress-tolerant breeding and molecular genetics. By utilizing Jijing 88 and 3 donor-derived breeding population selection, a novel segregation distortion locating process suitable for breeding population selection is adopted to locate drought-tolerance-related QTL (quantitative trait loci); and random population selection is utilized to verify the authenticity of the drought-tolerant QTL and the reliability of the close linkage marker. When being applied to auxiliary selective breeding and polymerization breeding of drought-tolerant rice, the gene can effectively overcome the defects in the past spontaneous mutant genes, can obviously lower the negative influence on the auxiliary breeding due to the development of the initial locating result, and can carry out genotype selection on the lower-generation breeding populations in the seedling stage to obtain the drought-tolerance individuals, thereby facilitating the timely hybrid transformation, omitting the drought resistance identification process in the adult-plant stage, enhancing the breeding efficiency and accelerating the breeding progress.

Proteases regulate a wide range of normal cellular functions where dysregulated activity is observed in various diseases. Compositions and methods use protease activity multiplexed bead-based immunoassays to profile protease activity. This platform technology integrates protease activity measurements with total protein quantification techniques. It represents a significant improvement over existing detection techniques by allowing for multiplexed, sensitive active protease measurements in complex biological samples. Exemplary multiplexed detections are realized in a single assay using a minute sample amount (e.g., 5 μl) for active recombinant MMP-1, -2, -3, -7, 9, and 12 and those same MMPs in cell culture supernatant, menstrual fluid effluent, and peritoneal aspirates. This multiplexed platform achieves high level of sensitivities equal to or better than existing leading single-plex detection strategies. It also allows for high throughput screening to identify inhibitors of proteases in complex, donor-derived samples.

The present invention pertains to a non-invasive method for monitoring transplanted organ status in organ-transplant recipients by determining the ratio of donor derived marker sequences to the marker sequences of the transplant recipient from circulating cell free DNA of the transplant recipients using digital droplet PCR. The invention also determined a normalized threshold value of the total circulating cell free nucleic acids healthy as well as in post-transplantation patients for assessing and monitoring transplanted organ status in organ-transplant recipients.

The present invention relates to a method for non-invasively predicting an organ transplant rejection by measuring the ratio between an organ-donor-specific nucleic acid sequence and a recipient-specific nucleic acid sequence in a biological sample of an organ transplant recipient and, more specifically, to a method for predicting an organ transplant rejection by measuring the ratio of a donor-derived marker sequence and a recipient-derived marker sequence regarding three or more markers selected in Tables 1 to 10 by testing a biological sample (e.g. blood) of an organ transplant recipient andpredicting the organ transplant rejection based on the measurement. The method for predicting an organ transplant rejection using next-generation sequencing (NGS) according to the present invention or a digital base amplification technique can apply even to a very small amount of sample, is faster and inexpensive, is fast in the rate of data analysis, can apply to all organ transplants of all races in the word, and can simultaneously detect error probability of a sequence analysis, and thus is useful to non-invasively predict the organ transplant rejection.

The present invention relates to a human chondroblastoma cell line and its application. The human chondroblastoma cell line has a deposit number of CCTCC NO: C2020110, and its donor source is a clinical histone H3.3K36M mutant chondroblastoma patient, and the 36th lysine on H3F3B is mutated to methionine Mutation of acid gene, the three-lineage differentiation of osteogenic, chondrogenic and adipogenic is blocked. It has the ability to form tumors in situ of the tibia and has stable tumorigenic ability. It can be transfected by lentivirus and has the function of gene modification. The human chondroblastoma cell line can be used for screening of drugs for the treatment of chondroblastoma, construction of a drug-resistant chondroblastoma model, construction of an animal model of chondroblastoma, screening of chondroblastoma-related biomarkers and research Mechanisms of the development of chondroblastoma. The invention provides experimental materials for researchers to deeply develop the occurrence and development mechanism of human chondroblastoma and to find or evaluate treatment plans.

Herein are novel methods of detecting subacute and active rejection in graft recipients, including kidney recipients by the measurement of donor-derived cell-free DNA. By the methods, active rejection processes encompassing T-cell mediated rejection may be detected. Also provided herein are novel threshold values for the determination of active rejection that enable higher sensitivity and specificity than prior methods. Additionally, by donor-derived cell-free DNA, subacute rejection processes can be detected, including borderline rejection and other graft injuries.

The invention discloses a new blood vessel construct for implanting into subcutaneous tissue of a subject and a preparation method thereof, and relates to the technical field of polymer materials. The neovascular construct is a nanofiber catheter made of the polymer material by electrospinning, and the material is selected from one of L-polylactic acid, D-polylactic acid, polylactic-co-glycolic acid copolymer and polyglycolic acid , the vascular construct prepared by using the polymer material is transplanted into the subcutaneous tissue, which can quickly form an extracellular matrix space rich in new blood vessels in the subcutaneous tissue of the subject, which is used to accommodate the donor-derived islets or islet cells for long-term maintenance of function.

The present invention pertains to a non-invasive method for monitoring transplanted organ status in organ-transplant recipients by determining the ratio of donor derived marker sequences to the marker sequences of the transplant recipient from circulating cell free DNA of the transplant recipients using digital droplet PCR. The invention also determined a normalized threshold value of the total circulating cell free nucleic acids healthy as well as in post-transplantation patients for assessing and monitoring transplanted organ status in organ-transplant recipients.

Described herein are methods and compositions for the treatment of skin conditions associated with dysbiosis. Skin conditions associated with dysbiosis for treatment using compositions and methods described herein include atopic dermatitis, eczema, dermatitis, psoriasis, rosacea, and acne. Compositions include single or more than one strain of healthy donor derived bacteria for administration to provide therapy for skin conditions associated with dysregulated microbiota. Such compositions include gram negative and / or gram positive bacteria.

The present invention discloses a method for determining the differential SNP between a donor and a receptor. The method comprises: obtaining first sequencing data and second sequencing data; respectively comparing the first sequencing data and the second sequencing data to a reference sequence to obtain a first comparing result and a second comparing result; respectively based on the first comparing result and the second comparing result, carrying out SNP detection to obtain a first typing results and a second typing result; and comparing the first typing result to the second typing results to determine the differential SNP. The invention discloses a method for determining the proportion of the donor-derived cfDNA in a receptor, and a method and an apparatus for monitoring organ transplant rejection. With the method and / or apparatus of the present invention, the differential SNP between the donor and the receptor can be determined, and the proportion of the donor-derived cfDNA in the receptor can be accurately determined. The method and / or the apparatus of the present invention can be adopted as the assisted or supplementing way for the organ transplant rejection monitoring.

The invention discloses a multi-batch primary separation method of same-donor-derived human mesenchymal stem cells, and belongs to the field of cell culture. According to the method, a donor tissue istreated to obtain 1 to 5 mm <3> donor tissue small blocks, and the donor tissue small blocks are soaked with fetal bovine serum or human AB serum for processing, and then subjected to conventional tissue block adherent culture. While harvesting of the mesenchymal stem cells, the donor tissue small blocks are transferred to a new culture plate for continuously culturing, and the culture supernatant of the tissue blocks is recovered and continuously incubated to achieve high-quality, multi-batch stable separation of the same-donor-derived human mesenchymal stem cells. The morphology, proliferation and differentiation ability and immunophenotype of the cells obtained by method remain unchanged among batches. Compared with a traditional tissue block adherence method and an enzymatic digestionmethod, the method avoids the waste of clinical specimen resources, saves human and material resources of clinical links, and improves the separation efficiency and yield of the mesenchymal stem cells.

Proteases regulate a wide range of normal cellular functions where dysregulated activity is observed in various diseases. Compositions and methods use protease activity multiplexed bead-based immunoassays to profile protease activity. This platform technology integrates protease activity measurements with total protein quantification techniques. It represents a significant improvement over existing detection techniques by allowing for multiplexed, sensitive active protease measurements in complex biological samples. Exemplary multiplexed detections are realized in a single assay using a minute sample amount (e.g., 5 μl) for active recombinant MMP-1, -2, -3, -7, 9, and 12 and those same MMPs in cell culture supernatant, menstrual fluid effluent, and peritoneal aspirates. This multiplexed platform achieves high level of sensitivities equal to or better than existing leading single-plex detection strategies. It also allows for high throughput screening to identify inhibitors of proteases in complex, donor-derived samples.

The invention relates to a method for detecting SNP sites of a donor-sourced sample and a receptor-sourced sample. Further, the present application also relates to a method for detecting the presence or proportion of donors in an acceptor sample, and a kit for implementing the method.

The invention discloses a multi-batch primary separation method of human mesenchymal stem cells from the same donor, belonging to the field of cell culture. The method of the present invention is to obtain a 1‑5mm tissue after the donor tissue is processed. 3 The small pieces of donor tissue were treated by soaking in fetal bovine serum or human AB serum, and then carried out conventional tissue block adherent culture. While harvesting mesenchymal stem cells, the donor tissue block is continuously cultured on a transfer plate, and the culture supernatant of the tissue block is recovered to continue incubation to achieve high-quality, multi-batch stable isolation of human mesenchymal stem cells from the same donor . The morphology, proliferation and differentiation ability and immunophenotype of the cells obtained in the present invention remain unchanged among batches. Compared with the traditional tissue block attachment method and enzyme digestion method, the method of the present invention avoids the waste of clinical specimen resources, saves manpower and material resources in clinical links, and also improves the separation efficiency and yield of mesenchymal stem cells.

The present invention relates to methods, combinations and pharmaceutical compositions for supplying a blood source from a donor source with a mis-matched blood type, or potentially a mis-matched blood type, to a recipient, using, inter alia, an effective amount of a nanoparticle comprising a) an inner core comprising a non-cellular material, and b) an outer surface comprising a cellular membrane derived from a red blood cell, the cellular membrane of the nanoparticle comprising a blood type antigen that exists on the red blood cell from the donor source, but is missing or potentially missing on red blood cells of the recipient.